Capricor Therapeutics is trading at $8.71, up 5.75%, with broad-market strength providing same-day context. - A November 4 market update reported major U.S. indexes higher as election uncertainty eased and futures surged. - November 3 reporting said 28 HOPE-3 investigators urged FDA leadership to approve deramiocel before the November 22 decision. Their letter was dated October 25, not a new event. - Capricor’s latest release schedules third-quarter results and a corporate update for November 10.